Perrigo Company plc (PRGO)
NYSE: PRGO · IEX Real-Time Price · USD
28.11
+0.04 (0.14%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Perrigo Company Revenue
Perrigo Company had revenue of $1.08B in the quarter ending March 30, 2024, a decrease of -8.43%. This brings the company's revenue in the last twelve months to $4.56B, down -0.06% year-over-year. In the year 2023, Perrigo Company had annual revenue of $4.66B with 4.58% growth.
Revenue (ttm)
$4.56B
Revenue Growth
-0.06%
P/S Ratio
0.84
Revenue / Employee
$498,457
Employees
9,140
Market Cap
3.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.66B | 204.00M | 4.58% |
| Dec 31, 2022 | 4.45B | 312.90M | 7.56% |
| Dec 31, 2021 | 4.14B | 50.50M | 1.24% |
| Dec 31, 2020 | 4.09B | 218.30M | 5.64% |
| Dec 31, 2019 | 3.87B | -861.80M | -18.21% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Jun 27, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Surgery Partners | 2.79B |
| Integer Holdings | 1.63B |
| Sotera Health Company | 1.08B |
| Neogen | 929.24M |
| Waystar Holding | 824.72M |
| Guardant Health | 603.73M |
| Corcept Therapeutics | 523.53M |
| Merus | 38.34M |
PRGO News
- 7 days ago - Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024 - PRNewsWire
- 16 days ago - Perrigo Completes Divestment of HRA Pharma Rare Diseases Business - PRNewsWire
- 4 weeks ago - Notice of Proposed Settlement and Plan of Allocation Involving Purchasers of Perrigo Common Stock from April 21, 2015 through May 2, 2017 and Owners of Perrigo Common Stock as of November 12, 2015 - GlobeNewsWire
- 2 months ago - Perrigo to Attend Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference - PRNewsWire
- 2 months ago - Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations - PRNewsWire
- 2 months ago - Perrigo Announces Executive Transition for its Consumer Self-Care International (CSCI) Business - PRNewsWire
- 3 months ago - Perrigo Announces Quarterly Dividend - PRNewsWire
- 3 months ago - Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million - PRNewsWire